Invention Grant
- Patent Title: Injectable suspension comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, and a method for the manufacturing thereof
-
Application No.: US16476377Application Date: 2018-01-09
-
Publication No.: US10933014B2Publication Date: 2021-03-02
- Inventor: Magnus Brisander , Karol Horvath , Björn Norrlind
- Applicant: ASARINA PHARMA AB
- Applicant Address: SE Solna
- Assignee: ASARINA PHARMA AB
- Current Assignee: ASARINA PHARMA AB
- Current Assignee Address: SE Solna
- Agency: Cermak Nakajima & McGowan LLP
- Agent Malcolm K. McGowan
- Priority: SE1750008-3 20170109
- International Application: PCT/EP2018/050453 WO 20180109
- International Announcement: WO2018/127601 WO 20180712
- Main IPC: A61K9/00
- IPC: A61K9/00 ; A61K9/10 ; A61K9/16 ; A61K31/57 ; A61K47/14 ; A61K47/28 ; C07J7/00 ; A61M5/32
Abstract:
The present invention relates to aseptic suspensions, physically stable and injectable through a 25G needle or thinner, comprising crystalline, non-micronized 3-beta-hydroxy-5-alpha-pregnan-20-one particles, a mixture of acylglycerols and cholesterol, processes for preparing crystalline, non-micronized, 3-beta-hydroxy-5-alpha-pregnan-20-one suitable for such suspensions, as well as methods for manufacturing such suspensions.
Public/Granted literature
- US20190350838A1 Injectable Suspensions Public/Granted day:2019-11-21
Information query
